Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
32
CSBTF Quote, Financials, Valuation and Earnings
Last price:
$32.00
Seasonality move
:
-7.58%
Day range:
$32.00 - $32.00
52-week range:
$19.44 - $42.81
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
9.78x
P/B ratio:
20.91x
Volume:
--
Avg. volume:
21
1-year change:
34.74%
Market cap:
$1.3B
Revenue:
$85.8M
EPS (TTM):
-$0.18
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -- | -- | -- | -- |
|
ACIU
AC Immune SA
|
$878.5K | -$0.13 | 11.32% | -18.31% | $9.20 |
|
BPMUF
Basilea Pharmaceutica AG
|
$93.1M | -- | -- | -- | -- |
|
ELVAF
EvoNext Holdings SA
|
-- | -- | -- | -- | -- |
|
ONC
BeOne Medicines Ltd.
|
$1.5B | $1.30 | 27.83% | 6689.47% | $409.68 |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CSBTF
Kuros Biosciences Ltd.
|
$32.00 | -- | $1.3B | -- | $0.00 | 0% | 9.78x |
|
ACIU
AC Immune SA
|
$2.84 | $9.20 | $285.7M | -- | $0.00 | 0% | 55.40x |
|
BPMUF
Basilea Pharmaceutica AG
|
$71.00 | -- | $871.3M | 19.33x | $0.00 | 0% | 3.46x |
|
ELVAF
EvoNext Holdings SA
|
$1.1700 | -- | $8.4M | 5.90x | $0.00 | 0% | 0.61x |
|
ONC
BeOne Medicines Ltd.
|
$299.02 | $409.68 | $33.1B | 118.52x | $0.00 | 0% | 6.33x |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
$21.15 | -- | $274.4M | 1.45x | $0.00 | 0% | 4.78x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -0.557 | -- | 1.61x |
|
ACIU
AC Immune SA
|
6.95% | 3.782 | 2.01% | 1.10x |
|
BPMUF
Basilea Pharmaceutica AG
|
85.07% | 0.818 | -- | 2.96x |
|
ELVAF
EvoNext Holdings SA
|
-- | 0.078 | -- | -- |
|
ONC
BeOne Medicines Ltd.
|
31.44% | 0.327 | 5.95% | 2.98x |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
33% | -7.351 | -- | 0.51x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -- | -6.35% | -6.35% | -- | -- |
|
ACIU
AC Immune SA
|
-- | -$19.6M | -72.31% | -75.88% | -1671.93% | -$24.4M |
|
BPMUF
Basilea Pharmaceutica AG
|
-- | -- | -0.84% | -15.42% | -- | -- |
|
ELVAF
EvoNext Holdings SA
|
-- | -- | -- | -- | -- | -- |
|
ONC
BeOne Medicines Ltd.
|
$1.3B | $185.8M | 5.51% | 7.54% | 12.35% | $381.2M |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
-- | -- | 123.12% | 276.68% | -- | -- |
Kuros Biosciences Ltd. vs. Competitors
-
Which has Higher Returns CSBTF or ACIU?
AC Immune SA has a net margin of -- compared to Kuros Biosciences Ltd.'s net margin of -1688.87%. Kuros Biosciences Ltd.'s return on equity of -6.35% beat AC Immune SA's return on equity of -75.88%.
Company Gross Margin Earnings Per Share Invested Capital CSBTFKuros Biosciences Ltd.-- -- $65M ACIUAC Immune SA-- -$0.20 $84.3M -
What do Analysts Say About CSBTF or ACIU?
Kuros Biosciences Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand AC Immune SA has an analysts' consensus of $9.20 which suggests that it could grow by 223.77%. Given that AC Immune SA has higher upside potential than Kuros Biosciences Ltd., analysts believe AC Immune SA is more attractive than Kuros Biosciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CSBTFKuros Biosciences Ltd.0 0 0 ACIUAC Immune SA4 0 0 -
Is CSBTF or ACIU More Risky?
Kuros Biosciences Ltd. has a beta of 0.916, which suggesting that the stock is 8.447% less volatile than S&P 500. In comparison AC Immune SA has a beta of 1.637, suggesting its more volatile than the S&P 500 by 63.73%.
-
Which is a Better Dividend Stock CSBTF or ACIU?
Kuros Biosciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kuros Biosciences Ltd. pays -- of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CSBTF or ACIU?
Kuros Biosciences Ltd. quarterly revenues are --, which are smaller than AC Immune SA quarterly revenues of $1.2M. Kuros Biosciences Ltd.'s net income of -- is lower than AC Immune SA's net income of -$19.8M. Notably, Kuros Biosciences Ltd.'s price-to-earnings ratio is -- while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kuros Biosciences Ltd. is 9.78x versus 55.40x for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSBTFKuros Biosciences Ltd.9.78x -- -- -- ACIUAC Immune SA55.40x -- $1.2M -$19.8M
-
Which has Higher Returns CSBTF or BPMUF?
Basilea Pharmaceutica AG has a net margin of -- compared to Kuros Biosciences Ltd.'s net margin of --. Kuros Biosciences Ltd.'s return on equity of -6.35% beat Basilea Pharmaceutica AG's return on equity of -15.42%.
Company Gross Margin Earnings Per Share Invested Capital CSBTFKuros Biosciences Ltd.-- -- $65M BPMUFBasilea Pharmaceutica AG-- -- $125.1M -
What do Analysts Say About CSBTF or BPMUF?
Kuros Biosciences Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Basilea Pharmaceutica AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Kuros Biosciences Ltd. has higher upside potential than Basilea Pharmaceutica AG, analysts believe Kuros Biosciences Ltd. is more attractive than Basilea Pharmaceutica AG.
Company Buy Ratings Hold Ratings Sell Ratings CSBTFKuros Biosciences Ltd.0 0 0 BPMUFBasilea Pharmaceutica AG0 0 0 -
Is CSBTF or BPMUF More Risky?
Kuros Biosciences Ltd. has a beta of 0.916, which suggesting that the stock is 8.447% less volatile than S&P 500. In comparison Basilea Pharmaceutica AG has a beta of 0.327, suggesting its less volatile than the S&P 500 by 67.337%.
-
Which is a Better Dividend Stock CSBTF or BPMUF?
Kuros Biosciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Basilea Pharmaceutica AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kuros Biosciences Ltd. pays -- of its earnings as a dividend. Basilea Pharmaceutica AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CSBTF or BPMUF?
Kuros Biosciences Ltd. quarterly revenues are --, which are smaller than Basilea Pharmaceutica AG quarterly revenues of --. Kuros Biosciences Ltd.'s net income of -- is lower than Basilea Pharmaceutica AG's net income of --. Notably, Kuros Biosciences Ltd.'s price-to-earnings ratio is -- while Basilea Pharmaceutica AG's PE ratio is 19.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kuros Biosciences Ltd. is 9.78x versus 3.46x for Basilea Pharmaceutica AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSBTFKuros Biosciences Ltd.9.78x -- -- -- BPMUFBasilea Pharmaceutica AG3.46x 19.33x -- --
-
Which has Higher Returns CSBTF or ELVAF?
EvoNext Holdings SA has a net margin of -- compared to Kuros Biosciences Ltd.'s net margin of --. Kuros Biosciences Ltd.'s return on equity of -6.35% beat EvoNext Holdings SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CSBTFKuros Biosciences Ltd.-- -- $65M ELVAFEvoNext Holdings SA-- -- -- -
What do Analysts Say About CSBTF or ELVAF?
Kuros Biosciences Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand EvoNext Holdings SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Kuros Biosciences Ltd. has higher upside potential than EvoNext Holdings SA, analysts believe Kuros Biosciences Ltd. is more attractive than EvoNext Holdings SA.
Company Buy Ratings Hold Ratings Sell Ratings CSBTFKuros Biosciences Ltd.0 0 0 ELVAFEvoNext Holdings SA0 0 0 -
Is CSBTF or ELVAF More Risky?
Kuros Biosciences Ltd. has a beta of 0.916, which suggesting that the stock is 8.447% less volatile than S&P 500. In comparison EvoNext Holdings SA has a beta of -40.297, suggesting its less volatile than the S&P 500 by 4129.699%.
-
Which is a Better Dividend Stock CSBTF or ELVAF?
Kuros Biosciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EvoNext Holdings SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kuros Biosciences Ltd. pays -- of its earnings as a dividend. EvoNext Holdings SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CSBTF or ELVAF?
Kuros Biosciences Ltd. quarterly revenues are --, which are smaller than EvoNext Holdings SA quarterly revenues of --. Kuros Biosciences Ltd.'s net income of -- is lower than EvoNext Holdings SA's net income of --. Notably, Kuros Biosciences Ltd.'s price-to-earnings ratio is -- while EvoNext Holdings SA's PE ratio is 5.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kuros Biosciences Ltd. is 9.78x versus 0.61x for EvoNext Holdings SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSBTFKuros Biosciences Ltd.9.78x -- -- -- ELVAFEvoNext Holdings SA0.61x 5.90x -- --
-
Which has Higher Returns CSBTF or ONC?
BeOne Medicines Ltd. has a net margin of -- compared to Kuros Biosciences Ltd.'s net margin of 4.44%. Kuros Biosciences Ltd.'s return on equity of -6.35% beat BeOne Medicines Ltd.'s return on equity of 7.54%.
Company Gross Margin Earnings Per Share Invested Capital CSBTFKuros Biosciences Ltd.-- -- $65M ONCBeOne Medicines Ltd.88.43% $0.58 $6.4B -
What do Analysts Say About CSBTF or ONC?
Kuros Biosciences Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $409.68 which suggests that it could grow by 37.03%. Given that BeOne Medicines Ltd. has higher upside potential than Kuros Biosciences Ltd., analysts believe BeOne Medicines Ltd. is more attractive than Kuros Biosciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CSBTFKuros Biosciences Ltd.0 0 0 ONCBeOne Medicines Ltd.17 0 1 -
Is CSBTF or ONC More Risky?
Kuros Biosciences Ltd. has a beta of 0.916, which suggesting that the stock is 8.447% less volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.532, suggesting its less volatile than the S&P 500 by 46.826%.
-
Which is a Better Dividend Stock CSBTF or ONC?
Kuros Biosciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kuros Biosciences Ltd. pays -- of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CSBTF or ONC?
Kuros Biosciences Ltd. quarterly revenues are --, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.5B. Kuros Biosciences Ltd.'s net income of -- is lower than BeOne Medicines Ltd.'s net income of $66.8M. Notably, Kuros Biosciences Ltd.'s price-to-earnings ratio is -- while BeOne Medicines Ltd.'s PE ratio is 118.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kuros Biosciences Ltd. is 9.78x versus 6.33x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSBTFKuros Biosciences Ltd.9.78x -- -- -- ONCBeOne Medicines Ltd.6.33x 118.52x $1.5B $66.8M
-
Which has Higher Returns CSBTF or SPHDF?
Santhera Pharmaceuticals Holding AG has a net margin of -- compared to Kuros Biosciences Ltd.'s net margin of --. Kuros Biosciences Ltd.'s return on equity of -6.35% beat Santhera Pharmaceuticals Holding AG's return on equity of 276.68%.
Company Gross Margin Earnings Per Share Invested Capital CSBTFKuros Biosciences Ltd.-- -- $65M SPHDFSanthera Pharmaceuticals Holding AG-- -- $79.8M -
What do Analysts Say About CSBTF or SPHDF?
Kuros Biosciences Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Santhera Pharmaceuticals Holding AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Kuros Biosciences Ltd. has higher upside potential than Santhera Pharmaceuticals Holding AG, analysts believe Kuros Biosciences Ltd. is more attractive than Santhera Pharmaceuticals Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings CSBTFKuros Biosciences Ltd.0 0 0 SPHDFSanthera Pharmaceuticals Holding AG0 0 0 -
Is CSBTF or SPHDF More Risky?
Kuros Biosciences Ltd. has a beta of 0.916, which suggesting that the stock is 8.447% less volatile than S&P 500. In comparison Santhera Pharmaceuticals Holding AG has a beta of -0.872, suggesting its less volatile than the S&P 500 by 187.184%.
-
Which is a Better Dividend Stock CSBTF or SPHDF?
Kuros Biosciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Santhera Pharmaceuticals Holding AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kuros Biosciences Ltd. pays -- of its earnings as a dividend. Santhera Pharmaceuticals Holding AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CSBTF or SPHDF?
Kuros Biosciences Ltd. quarterly revenues are --, which are smaller than Santhera Pharmaceuticals Holding AG quarterly revenues of --. Kuros Biosciences Ltd.'s net income of -- is lower than Santhera Pharmaceuticals Holding AG's net income of --. Notably, Kuros Biosciences Ltd.'s price-to-earnings ratio is -- while Santhera Pharmaceuticals Holding AG's PE ratio is 1.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kuros Biosciences Ltd. is 9.78x versus 4.78x for Santhera Pharmaceuticals Holding AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSBTFKuros Biosciences Ltd.9.78x -- -- -- SPHDFSanthera Pharmaceuticals Holding AG4.78x 1.45x -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
93
NBTX alert for Mar 5
Nanobiotix SA [NBTX] is down 6.9% over the past day.
Sell
45
MRNA alert for Mar 5
Moderna, Inc. [MRNA] is down 8.91% over the past day.
Buy
77
SSRM alert for Mar 5
SSR Mining, Inc. [SSRM] is down 6.46% over the past day.
